As current MDIs contain hydrofluorocarbon propellants, it would be beneficial to find ways to reduce carbon emissions without compromising patient safety.
This lab study investigated a way to optimize the modelled lung dose per actuation while at the same time minimizing the carbon emissions from the MDI
Nouveautés Loi 31 – Enfin! Mais comment faire mieux avec nos patients en santé respiratoire?
L’ajout récent des prises en charge pour l’asthme et la MPOC dans les actes de la Loi 31 est une opportunité intéressante et rentable d’améliorer la santé respiratoire des patients. Ce webinaire vous permettra de mettre à jour vos connaissances en santé respiratoire, d’obtenir des outils pratiques afin de réaliser ces actes dans vos pharmacies et d’apprivoiser leur facturation. Un événement à ne pas manquer!
Est-ce une MPOC, une Fibrose, de l’Asthme…NON, C’est une bronchiectasie! Plein feux sur une meilleur prise en charge de cette pathologie!
Joignez-vous à Isabelle LeClerc, Infirmière praticienne, pour une discussion accréditée sur la bronchiectasie afin d'en savoir plus sur ce qui rend cette maladie respiratoire unique. Ensemble, nous découvrirons comment vous pouvez aider vos patients atteints de bronchiectasie à mieux respirer grâce à une approche non-pharmacologique ainsi qu’une bonne autogestion pour finalement améliorer leur qualité de vie.
As current MDIs contain hydrofluorocarbon propellants, it would be beneficial to find ways to reduce carbon emissions without compromising patient safety.
This lab study investigated a way to optimize the modelled lung dose per actuation while at the same time minimizing the carbon emissions from the MDI
Cystic fibrosis (CF) is a progressive, genetic condition affecting more than 100,000 people worldwide.1 There are over 4,300 people living with CF in Canada.2
The FRI deposition profiles highlighted significant differences between the VHCs on test, with intrathoracic delivery for the AeroChamber Plus* Flow-Vu* VHC system being almost double that of the other two VHC systems and being similar to the MDI alone with perfect coordination
A systematic review of nebulizer use highlighted a few different potential mechanisms for fugitive emissions. Differences in nebulizer design had an impact in the amount and type of fugitive emissions emitted.
Through the choice of an appropriate nebulizer, the natural risk can be greatly reduced, and through selection of appropriate mitigation strategies, the risk can be almost eliminated.
A systematic review of nebulizer use highlighted a few different potential mechanisms for fugitive emissions. Differences in nebulizer design had an impact in the amount and type of fugitive emissions emitted.
Through the choice of an appropriate nebulizer, the natural risk can be greatly reduced, and through selection of appropriate mitigation strategies, the risk can be almost eliminated.
Inhaled tobramycin is recommended for use in cystic fibrosis patients for treatment of Pseudomonas aeruginosa infection. This in vitro study looked at antibiotic delivery using a BA nebulizer/compressor system and two BE nebulizer/compressor systems.
